最新临床试验：达布拉非尼联合曲美替尼治疗不能手术切除的Ⅲ-Ⅳ期BRAF突变性黑色素瘤

这个随机的II期临床试验，其研究目的是达布拉非尼和曲美替尼在治疗III-IV期黑色素瘤患者中的作用如何。III-IV期黑色素瘤患者不能通过手术切除，并且纳入试验的患者含有B-Raf原癌基因、丝氨酸/苏氨酸激酶（BRAF）突变。达布拉非尼和曲美替尼可能通过阻断细胞生长所需的一些酶来阻止肿瘤细胞的生长。

This randomized phase II trial studies how well dabrafenib and trametinib work in treating patients with stage III-IV melanoma that cannot be removed by surgery and contains a B-Raf proto-oncogene, serine / threonine kinase (BRAF) mutation. Dabrafenib and trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Trial Phase & Type